January 24, 2023

New Oral Compound Developed by Mass General Researchers May Help Prevent and Treat Osteoporosis

Parathyroid hormone can stimulate bone formation, and analogs of the hormone are often prescribed to patients with osteoporosis; however, these medications are only effective when administered by daily injection.

A team led by investigators at Massachusetts General Hospital (MGH) recently identified a promising compound that influences components of the parathyroid hormone signaling pathway and that, when given orally to mice, increases bone mass. The group’s discovery, which is published in PNAS, might lead to a new, more convenient drug for preventing and treating osteoporosis.

“Currently there are no orally available medications for osteoporosis that stimulate bone formation. We sought to develop such medications based upon our detailed understanding of the pathways that normally govern bone production,” says senior author Marc Wein, MD, PhD, an endocrinologist at MGH and an Assistant Professor of Medicine at Harvard Medical School.

The pathway that involves parathyroid hormone inhibits salt-inducible kinase isoforms 2 and 3 (SIK2 and SIK3), which are enzymes with roles in the regulation of bone growth and remodeling.

Wein and his colleagues generated a novel structural model of these enzymes and then used advanced methods including structure-based drug design and iterative medicinal chemistry to identify a compound that potently inhibits SIK2 and SIK3. This compound, termed SK-124, had parathyroid hormone–like effects when given to cells and, most importantly, when fed to mice. In mice, oral treatment once a day for three weeks increased blood levels of calcium and vitamin D and also boosted bone formation and bone mass without evidence of short-term toxicity.

Key Takeaways

• Parathyroid hormone–based medications can stimulate bone formation to treat osteoporosis but are only effective when administered by injection
• Researchers have now identified an oral compound that influences components of the parathyroid hormone signaling pathway to increase bone formation and bone mass in mice
• The investigators are currently working to optimize and develop this compound into a new therapy for patients

Read the full press release on EurekAlert.

About the Scholar

Endocrine, Musculoskeletal

Marc Wein, MD, PhD

Massachusetts General Hospital
Harrington Scholar-Innovator

More about Marc Wein